Uveitis Clinical Trial - Retrospective Comparison of the Efficacy of

Status Not yet recruiting

Clinical Trial Summary

Retrospective study at the Brest universitary hospital to evaluate the efficacy of methotrexate (MTX) and azathioprine (AZA) in background treatment of unidentified non anterior uveitis.

Clinical Trial Description

Uveitis is a major cause of ocular damage, responsible for 5 to 10% of blindness in the world. More broadly, up to 35% of patients with uveitis have visual acuity impairment ranging from "significant" to "legal blindness" [4]. The figures of "legal blindness" up to 25% according to the studies The objective of any anti-inflammatory therapy strategy for uveitis is to: - Quickly control eye inflammation to minimize irreversible structural damage and maintain visual function. - Prevent inflammatory recurrences, which cause complications and co-morbidity. - Limit the use of systemic corticosteroids over the course of their deleterious metabolic effects. - Optimize the risk-benefit balance and promote compliance. The studies concerning uveitis linked with another disease are multiple and are therefore well documented. Uveitis of undetermined origin is classified, by definition, as uveitis of non-infectious origin. Anterior uveitis are available for local treatment prior to any discussion of introducing systemic treatment. Intermediate uveitis, posterior and panuveitis justify systemic treatment. Systemic treatments used in these uveitis are METHOTREXATE, AZATHIOPRINE, MYCOPHENOLATE MOFETIL CICLOSPORINE, INTERFERON ALPHA, anti-TNF alpha. Antimetabolites (azathioprine, mycophenolate mofetil and methotrexate) are the most commonly used immunosuppressants. Several randomized studies (retrospective or prospective) compared the use of METHOTREXATE (MTX) and MYCOPHENOLATE MOFETIL (MMF), in the management of non-infectious inflammatory ocular disease as a corticosteroid-sparing treatment. Although MMF has a faster response time compared to MTX for inflammation control, the success rate is equivalent. These studies found no superiority of one molecule over the other . There are no studies in the literature comparing the use of MTX versus AZA in treatment of these non-prior uveitis of undetermined origin. These two molecules are frequently used in our center as first-line treatment of idiopathic uveitis in an undifferentiated way. The objective of this study is therefore to determine whether one of these molecules should be preferred for the management of our patients. ;

Study Design

Related Conditions & MeSH terms

Uveitis

Clinical Trial Details

NCT number	NCT05370690
Study type	Observational
Source	University Hospital, Brest
Contact	Bénédicte ROUVIERE, PhD
Phone	02 98 34 73 36
Email	benedicte.rouviere@chu-brest.fr
Status	Not yet recruiting
Phase
Start date	May 1, 2022
Completion date	November 1, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04101604` - Biomarkers of Common Eye Diseases
Active, not recruiting	`NCT04704609` - Imaging Quantification of Inflammation (IQI)
Completed	`NCT03173144` - Chronic Inflammatory Disease, Lifestyle and Treatment Response
Withdrawn	`NCT01280669` - Intravitreal Sirolimus as Therapeutic Approach to Uveitis	Phase 2
Terminated	`NCT02907814` - Measurement of Anterior Chamber Cell Grading Using Ocular Coherence Tomography	N/A
Active, not recruiting	`NCT02252328` - Use of Simvastatin as a Steroid Sparing Agent for Uveitis Patients	Phase 2/Phase 3
Completed	`NCT04183387` - Simvastatin in Uveitis	Phase 2
Completed	`NCT01983488` - Clinical Outcome in Uveitis
Withdrawn	`NCT00499551` - A Phase I/IIa Study for the Treatment of Uveitis With Iontophoresis	Phase 1/Phase 2
Completed	`NCT00132691` - Multicenter Uveitis Steroid Treatment (MUST) Trial	Phase 4
Terminated	`NCT00114062` - Study to Treat Uveitis Associated Macular Edema	Phase 2
Completed	`NCT00476593` - Retinal OCT and (mfERG) Related to Age, Sex, and the Use of Anti-inflammatory Medications	N/A
Completed	`NCT00001867` - Effect of Pregnancy on Uveitis	N/A
Completed	`NCT00379275` - Eye and Immunogenetic Features of Sarcoidosis	N/A
Active, not recruiting	`NCT03828019` - Adalimumab vs. Conventional Immunosuppression for Uveitis Trial	Phase 3
Terminated	`NCT01939691` - Macular Edema Nepafenac vs. Difluprednate Uveitis Trial	Phase 4
Active, not recruiting	`NCT03889860` - Objective Choroidal Thickness Measurements in Uveitis
Completed	`NCT00070759` - Daclizumab to Treat Non-Infectious Sight-Threatening Uveitis	Phase 2
Recruiting	`NCT05486468` - The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment	Phase 3
Active, not recruiting	`NCT05385757` - UNICORNS: Uveitis in Childhood Prospective National Cohort Study

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Retrospective Comparison of the Efficacy of Methotrexate and Azathioprine as Background Treatment for Uveitis of Undetermined Origin: Single-centre Retrospective Study From 2005 to 2020 — UMetAza

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms